Marquette Asset Management LLC Sells 26,068 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

Marquette Asset Management LLC lowered its stake in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) by 31.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 57,911 shares of the biotechnology company’s stock after selling 26,068 shares during the quarter. Marquette Asset Management LLC’s holdings in Aclaris Therapeutics were worth $144,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of ACRS. Point72 Asia Singapore Pte. Ltd. purchased a new position in Aclaris Therapeutics during the second quarter worth $119,000. Assenagon Asset Management S.A. bought a new stake in shares of Aclaris Therapeutics in the 3rd quarter worth about $214,000. Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Aclaris Therapeutics by 187.6% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 332,406 shares of the biotechnology company’s stock worth $382,000 after purchasing an additional 216,826 shares during the period. Geode Capital Management LLC boosted its stake in shares of Aclaris Therapeutics by 9.3% during the 3rd quarter. Geode Capital Management LLC now owns 846,446 shares of the biotechnology company’s stock worth $974,000 after purchasing an additional 72,309 shares during the period. Finally, Jacobs Levy Equity Management Inc. bought a new position in Aclaris Therapeutics during the 3rd quarter valued at about $1,053,000. Hedge funds and other institutional investors own 98.34% of the company’s stock.

Aclaris Therapeutics Trading Up 0.8 %

Shares of ACRS stock opened at $2.50 on Wednesday. Aclaris Therapeutics, Inc. has a twelve month low of $0.95 and a twelve month high of $5.17. The stock has a fifty day simple moving average of $3.09 and a two-hundred day simple moving average of $1.91. The stock has a market capitalization of $178.58 million, a price-to-earnings ratio of -4.81 and a beta of 0.54.

Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.03). Aclaris Therapeutics had a negative net margin of 136.65% and a negative return on equity of 40.26%. The firm had revenue of $4.35 million during the quarter, compared to the consensus estimate of $8.31 million. Research analysts predict that Aclaris Therapeutics, Inc. will post -0.75 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. HC Wainwright upgraded Aclaris Therapeutics from a “neutral” rating to a “buy” rating and set a $20.00 target price for the company in a research report on Monday, December 23rd. StockNews.com upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, November 15th. Jefferies Financial Group upgraded Aclaris Therapeutics from a “hold” rating to a “buy” rating and increased their target price for the stock from $2.00 to $7.00 in a research note on Tuesday, November 19th. Leerink Partnrs upgraded Aclaris Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, November 19th. Finally, BTIG Research upgraded shares of Aclaris Therapeutics from a “neutral” rating to a “buy” rating and set a $8.00 price target on the stock in a report on Tuesday, November 19th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Aclaris Therapeutics has a consensus rating of “Buy” and a consensus price target of $11.00.

Insider Activity

In other Aclaris Therapeutics news, Director Anand Mehra acquired 666,666 shares of the company’s stock in a transaction dated Tuesday, November 19th. The shares were purchased at an average cost of $2.25 per share, for a total transaction of $1,499,998.50. Following the completion of the purchase, the director now owns 710,030 shares in the company, valued at approximately $1,597,567.50. This trade represents a 1,537.37 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 6.40% of the company’s stock.

Aclaris Therapeutics Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.